Posts

Posted on

$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $shareholders to Act Before the Vote—UBFO, CWBC, NWE, and WBS

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

  • United Security Bancshares (NASDAQ: 

    UBFO

    ) related to its sale to Community West Bancshares. Under the terms of the proposed transaction, United Security shareholders are expected to receive 0.4520 shares of Community West common stock for each share of United Security common stock.

ACT NOW. The Shareholder Vote is scheduled for March 30, 2026.

Click here for more information

https://monteverdelaw.com/case/united-security-bancshares/

. It is free and there is no cost or obligation to you.

  • Community West Bancshares (NASDAQ: 

    CWBC

    ) related to its merger with United Security Bancshares. Under the terms of the proposed transaction, United Security shareholders are expected to receive 0.4520 shares of Community West common stock for each share of United Security common stock.

ACT NOW. The Shareholder Vote is scheduled for March 30, 2026.

Click here for more information

https://monteverdelaw.com/case/community-west-bancshares/

. It is free and there is no cost or obligation to you.

  • NorthWestern Energy Group, Inc. (NASDAQ: 

    NWE

    ) related to its sale to Black Hills Corp. Under the terms of the proposed transaction, NorthWestern shareholders will receive 0.98 shares of Black Hills for each share of NorthWestern. Upon completion of the transaction, NorthWestern shareholders will own approximately 44% of the combined company.

ACT NOW. The Shareholder Vote is scheduled for April 2, 2026.

Click here for more information

https://monteverdelaw.com/case/northwestern-energy-group-inc/

. It is free and there is no cost or obligation to you.

  • Webster Financial Corporation (NYSE: 

    WBS

    ) related to its sale to Banco Santander, S.A. Under the terms of the proposed transaction, Webster shareholders are expected to receive $48.75 in cash and 2.0548 Santander American Depository Shares for each Webster common share.

Click here for more info

https://monteverdelaw.com/case/webster-financial-corporation/

.
It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

  1. Do you file class actions and go to Court?
  2. When was the last time you recovered money for shareholders?
  3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.



Posted on

$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote—BHRB, LNKB, HTBK, and CVBF

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) —

Class Action Attorney
Juan Monteverde
with

Monteverde & Associates PC
 (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

  • Burke & Herbert Financial Services Corp. (NASDAQ: 

    BHRB

    ) related to its merger with LINKBANCORP, Inc. Upon completion of the proposed transaction, Burke & Herbert shareholders are expected to own approximately 75% of the combined company.

ACT NOW. The Shareholder Vote is scheduled for March 25, 2026.

Click here for more information

https://monteverdelaw.com/case/burke-herbert-financial-services-corp/

. It is free and there is no cost or obligation to you.

  • LINKBANCORP, Inc. (NASDAQ: 

    LNKB

    ) related to its sale to Burke & Herbert Financial Services Corp. Under the terms of the proposed transaction, LINKBANCORP shareholders are expected to receive 0.1350 shares of Burke & Hebert common stock for each share of LINKBANCORP common stock.

ACT NOW. The Shareholder Vote is scheduled for March 25, 2026.

Click here for more information

https://monteverdelaw.com/case/linkbancorp-inc/

. It is free and there is no cost or obligation to you.

  • Heritage Commerce Corp (NASDAQ: 

    HTBK

    ) related to its sale to CVB Financial Corp. Under the terms of the proposed transaction, Heritage shareholders are expected to receive 0.6500 shares of CVB common stock for each share of Heritage.

ACT NOW. The Shareholder Vote is scheduled for March 26, 2026.

Click here for more information

https://monteverdelaw.com/case/heritage-commerce-corp/

. It is free and there is no cost or obligation to you.

  • CVB Financial Corp. (NASDAQ: 

    CVBF

    ) related to its merger with Heritage Commerce Corp. Upon completion of the proposed transaction, CVB shareholders will own approximately 77% of the combined company.

ACT NOW. The Shareholder Vote is scheduled for March 26, 2026.

Click here for more info

https://monteverdelaw.com/case/cvb-financial-corp/

.
It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

  1. Do you file class actions and go to Court?
  2. When was the last time you recovered money for shareholders?
  3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.



Posted on

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–
Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, at 4:30 p.m. ET, after market close.

The company will issue a press release detailing its fourth quarter and full year financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/.

Following the release, management will host a conference call to review financial and operating results.

Conference Call Information:

To participate in the conference call, please use the dial-in information below:

Participant Listening: 1-877-407-9039 or 1-201-689-8470

or

https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6

Participants can use guest dial-in #s above and be answered by an operator, or click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time.

The live audio webcast will be accessible here:

https://viavid.webcasts.com/starthere.jsp?ei=1753776&tp_key=c7346c57d0

A replayof the earnings call is available after the conference call has ended.

Replay Dial-In:

1-844-512-2921 or 1-412-317-6671

Access ID:13758917

Replay Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1753776&tp_key=c7346c57d0

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL® is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s [Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at www.sec.gov.] These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

For further information:

Investor Relations

[email protected]

https://www.alphacognition.com/

KEYWORDS: Texas United States North America Canada

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Neurology

MEDIA:

Logo
Logo
Posted on

Toll Brothers Unveils Two Brand-New Home Designs at Cross Kirkland Towns in Kirkland, Washington

Luxury townhomes in a prime location with direct access to the Cross Kirkland Corridor trail system

KIRKLAND, Wash., March 13, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, announced the release of two brand-new home designs at Cross Kirkland Towns, a luxury townhome community in Kirkland, Washington. Unique to the first building being released, the new Curlew and Grayland home designs feature a covered patio on the main living level that opens to a fenced rear yard, offering a seamless indoor/outdoor living experience. The Toll Brothers Sales Center and model homes are located at 10829 120th Lane NE in Kirkland.

Cross Kirkland Towns offers luxury four-bedroom townhomes ranging from 1,904 to 2,421 square feet, each with 3.5 baths and a 2-car garage. The community’s unique northwest contemporary architecture is complemented by sleek interior finishes and thoughtfully designed layouts, including private first-floor bedrooms with full bathrooms and flex spaces ideal for home offices in select designs. Pricing starts from $1.2 million.

Residents at Cross Kirkland Towns enjoy direct access to the Cross Kirkland Corridor section of the Eastrail trail system, a picturesque 42-mile trail connecting neighborhoods and transit hubs throughout the region. This trail offers both recreational and commuting opportunities, enhancing the active lifestyle of residents. Additional community amenities include a pickleball court, dog park, children’s playground, and open spaces connected by pedestrian paths and paseos.

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

“Cross Kirkland Towns offers a unique combination of luxury living, thoughtful design, and connectivity to the surrounding community,” said Todd Callahan, Regional President of Toll Brothers for the Pacific region. “The addition of the Curlew and Grayland home designs provides more options for home shoppers looking for the perfect home in an exceptional location.”

Ideally situated in the Lake Washington School District, the community is served by Alexander Graham Bell Elementary, Finn Hill Middle, and Juanita High Schools. With its central location, Cross Kirkland Towns offers easy access to dining, shopping, and recreation in downtown Kirkland, Juanita Beach, and The Village at Totem Lake. The community is also a short commute to major employment centers, including Microsoft, Meta, and Amazon.

For more information on Cross Kirkland Towns and Toll Brothers communities throughout Washington, call 844-845-5263 or visit TollBrothers.com/WA.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bc4e11f4-885e-4147-94d3-294bc1954481

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)



Posted on

Shareholders who lost money in shares Eos Energy Enterprises, Inc. (NASDAQ: EOSE) should contact Wolf Haldenstein immediately

Lead Plaintiff Deadline is May 5, 2026

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of persons and entities that purchased or otherwise acquired Eos Energy Enterprises (“Eos Energy” or the “Company”) (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026, inclusive (the “Class Period”). Investors have until May 8, 2026, to seek appointment as lead plaintiff.



PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Eos Energy manufactures zinc-based long-duration battery energy storage systems used to store renewable power and support grid reliability.

Eos repeatedly touted manufacturing progress driven by a transition to a highly automated battery manufacturing line and issued revenue guidance of $150 million to $160 million for fiscal year 2025.

The filed complaint alleges that Company statements were materially false and misleading because Eos was experiencing significant production inefficiencies, excessive battery line downtime, and delays in achieving quality targets, which undermined its ability to meet its stated guidance.

On February 26, 2026, before the market opened, Eos reported a substantial net loss of approximately $970 million for fiscal year 2025 and disclosed full‑year 2025 revenue that fell short of the guidance the company had repeatedly reaffirmed due to heavy spending to scale its manufacturing operations, including ramp‑up inefficiencies, automation‑related costs, and
large non‑cash financing and asset write‑down charges. Eos also issued weaker‑than‑expected 2026 revenue guidance due to slower‑than‑anticipated production progress and heightened execution risk.

Following these disclosures, Eos Energy’s stock price fell $4.39 per share, or approximately 39.4%, to close at $6.74.

Investors who suffered losses have until May 5, 2026, to seek appointment as lead plaintiff.


Why Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

Firm Website: 
Wolf Haldenstein Adler Freeman & Herz LLP



Posted on

Kuehn Law Encourages Investors of Nutex Health, Inc. to Contact Law Firm

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Nutex Health caused the company to misrepresent or fail to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company’s engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex’s business and/or financial prospects were overstated; and (viii) as a result, public statements were materially false and misleading at all relevant times.

If you currently own NUTX and purchased prior to August 8, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Kuehn Law Encourages Investors of C3.ai, Inc. to Contact Law Firm

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of C3.ai, Inc. (NYSE: AI) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at C3.ai caused the company to misrepresent or fail to disclose material adverse facts concerning the true state of C3 AI’s growth; notably, that its Chief Executive Officer’s health was having a significant impact on the Company’s ability to close deals, that its management was unable or otherwise ineffectual in minimizing that impact, and that C3 AI would not be able to execute upon its profit and growth potential as a result.

If you currently own AI and purchased prior to February 26, 2025 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Kuehn Law Encourages Investors of PubMatic, Inc. to Contact Law Firm

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of PubMatic, Inc. (NASDAQ: PUBM) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at PubMatic caused the company to misrepresent or fail to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that a top DSP buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) that, as a result, PubMatic was seeing a reduction in ad spend and revenue from this top DSP buyer; and (3) that, as a result of the foregoing, positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you currently own PUBM and purchased prior to February 27, 2025 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Kuehn Law Encourages Investors of Snap, Inc. to Contact Law Firm

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Snap, Inc. (NYSE: SNAP) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Snap caused the company to misrepresent or fail to disclose material adverse facts concerning the true state of Snap’s advertising revenue growth rate; notably, that, due to Snap’s own execution failure, it had significantly declined from 9% in the first quarter to only 1% in April.

If you currently own SNAP and purchased prior to April 29, 2025 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

FIGS-Developed Healthcare is Human Act Introduced in Congress to Provide Federal Tax Credit for Healthcare Professionals

FIGS-Developed Healthcare is Human Act Introduced in Congress to Provide Federal Tax Credit for Healthcare Professionals

Bipartisan legislation sponsored by Rep. Claudia Tenney (R-NY) and Rep. Steven Horsford (D-NV) recognizes healthcare professionals for their extraordinary sacrifices and addresses understaffing and burnout

SANTA MONICA, Calif.–(BUSINESS WIRE)–
FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand, announced the introduction of the Healthcare is Human Act, a milestone bipartisan bill sponsored by Representatives Claudia Tenney (R-NY) and Steven Horsford (D-NV). Developed in partnership with FIGS, the Tenney-Horsford legislation provides a federal tax credit of up to $6,000 per year to healthcare professionals serving communities most impacted by shortages — directly addressing low pay as a driver of burnout, turnover, and dangerous understaffing across the healthcare workforce.

The Healthcare is Human Act is designed to solve a critical problem facing the healthcare workforce. According to the federal Health Services and Resources Administration’s most recent report, more than 8,200 primary care, 7,200 dental, and 6,600 mental health shortage areas exist nationwide in rural and urban communities alike. To address these shortages, the nation needs to significantly increase the size of the healthcare workforce. This legislation provides a well-deserved financial reward to help retain the Awesome Humans who are currently working in these communities and an incentive to others to join them. Implementing this important legislation will ultimately lead to communities across the country receiving the care they deserve.

The bill introduction builds on momentum from FIGS’ Awesome Humans on the Hill advocacy day in June 2025, when 18 healthcare professionals joined actor Noah Wyle and his mother Marty Wyle (a nurse of 50 years) on Capitol Hill to call for bold action on fair pay and other critical healthcare workforce issues. Today’s introduction shows that their voices were heard.

Trina Spear, CEO and Co-Founder of FIGS: “Healthcare is human — it’s about real people who give everything of themselves to care for others. Yet too many are underpaid and undervalued, creating a deep unfairness for healthcare professionals as well as staffing shortages that cause serious social harm. The Healthcare is Human Act is historic: a federal bill to reward healthcare professionals with a tax credit for their extraordinary service. We are deeply grateful to Rep. Tenney and Rep. Horsford for leading this important bipartisan effort to recognize and support them.”

Representative Claudia Tenney: “Across Upstate New York and rural communities nationwide, too many families struggle to access timely medical care because there simply are not enough providers serving these areas,” said Congresswoman Tenney. “The Healthcare is Human Act provides meaningful incentives for doctors, nurses, and other licensed professionals to deliver care where it is needed most, including in health professional shortage areas and facilities serving our veterans. Strengthening our health care workforce is essential to ensuring families receive the care they deserve, and that rural and underserved communities are never left behind.”

Representative Steven Horsford: “Communities across Nevada know firsthand the consequences of healthcare workforce shortages. Every one of Nevada’s 17 counties, urban and rural alike, is designated as a Health Professional Shortage Area. As a result, too many Nevadans are forced to travel farther, wait longer, or go without the care they need. The Healthcare is Human Act provides a well-deserved financial incentive through a tax credit to help recruit and retain healthcare providers serving similarly situated communities. The least we can do is provide meaningful support for these frontline workers who dedicate their lives to caring for our communities.”

Farida Labaran, RN, FIGS Ambassador: “When we came to Capitol Hill in June, we told Congress what life looks like for healthcare professionals — deep meaning and satisfaction in caring for others, and also the long hours, and the financial stress that many of us face to pay for our education and training. To see this bill introduced shows that our stories made an impact. This is a step toward a future where healthcare professionals feel more respected, supported, and truly valued.”

What the bill does:

  • Creates a nonrefundable federal income tax credit of up to $500 per month for healthcare professionals with annual income of under $200,000 (or $400,000 for joint filers/surviving spouses).

  • Generally applies to licensed healthcare professionals providing at least 80 hours per month of care for at least 8 months of the year in a qualifying facility.

  • Qualifying facilities must be enrolled in Medicare or Medicaid and located in a federally designated Health Professional Shortage Area (HPSA), or be a Department of Veterans Affairs medical facility.

About FIGS

FIGS is a founder-led, direct-to-consumer healthcare apparel and lifestyle brand that seeks to celebrate, empower and serve current and future generations of healthcare professionals. We create technically advanced apparel and products that feature an unmatched combination of comfort, durability, function and style. We share stories about healthcare professionals’ experiences in ways that inspire them. We build meaningful connections within the healthcare community that we created. Above all, we seek to make an impact for our community, including by advocating for them and always having their backs.

We serve healthcare professionals both in the U.S. and internationally. We also serve healthcare institutions through our TEAMS platform.

Investors:

Tom Shaw

[email protected]

Media:

Todd Maron

[email protected]

KEYWORDS: Nevada California New York United States North America

INDUSTRY KEYWORDS: Nursing Specialty Public Policy/Government Practice Management Fashion White House/Federal Government Managed Care General Health Health Retail

MEDIA: